Procalcitonin Guidance of Antibiotic Therapy in Community-acquired Pneumonia
Top Cited Papers
- 1 July 2006
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 174 (1) , 84-93
- https://doi.org/10.1164/rccm.200512-1922oc
Abstract
In patients with community-acquired pneumonia, guidelines recommend antibiotic treatment for 7 to 21 d. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications. To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia. In a randomized intervention trial, 302 consecutive patients with suspected community-acquired pneumonia were included. Data were assessed at baseline, after 4, 6, and 8 d, and after 6 wk. The control group (n = 151) received antibiotics according to usual practice. In the procalcitonin group (n = 151), antibiotic treatment was based on serum procalcitonin concentrations as follows: strongly discouraged, less than 0.1 microg/L; discouraged, less than 0.25 microg/L; encouraged, greater than 0.25 microg/L; strongly encouraged, greater than 0.5 microg/L. The primary endpoint was antibiotic use; secondary endpoints were measures of clinical, laboratory, and radiographic outcome. At baseline, both groups were similar regarding clinical, laboratory, and microbiology characteristics, and Pneumonia Severity Index. Procalcitonin guidance reduced total antibiotic exposure (relative risk, 0.52; 95% confidence interval, 0.48-0.55; p < 0.001), antibiotic prescriptions on admission (85 vs. 99%; p < 0.001), and antibiotic treatment duration (median, 5 vs. 12 d; p < 0.001) compared with patients treated according to guidelines. After adjustment for Pneumonia Severity Index, the hazard ratio of antibiotic discontinuation was higher in the procalcitonin group than in the control group (3.2; 95% confidence interval, 2.5 to 4.2). Outcome was similar in both groups, with an overall success rate of 83%. Procalcitonin guidance substantially reduces antibiotic use in community-acquired pneumonia. These findings may have important clinical and public health implications.Keywords
This publication has 51 references indexed in Scilit:
- Reaching Stability in Community-Acquired Pneumonia: The Effects of the Severity of Disease, Treatment, and the Characteristics of PatientsClinical Infectious Diseases, 2004
- Limits to the use of the procalcitonin level as a diagnostic marker.Clinical Infectious Diseases, 2004
- Clinical Efficacy of Newer Agents in Short-Duration Therapy for Community-Acquired PneumoniaClinical Infectious Diseases, 2004
- Double-Blind, Randomized Study of the Efficacy and Safety of Oral Pharmacokinetically Enhanced Amoxicillin-Clavulanate (2,000/125 Milligrams) versus Those of Amoxicillin-Clavulanate (875/125 Milligrams), Both Given Twice Daily for 7 Days, in Treatment of Bacterial Community-Acquired Pneumonia in AdultsAntimicrobial Agents and Chemotherapy, 2004
- Editorial Commentary: Short‐Course Treatment of Community‐Acquired PneumoniaClinical Infectious Diseases, 2003
- Editorial Commentary: What is Optimal Antimicrobial Therapy for Bacteremic Pneumococcal Pneumonia?Clinical Infectious Diseases, 2003
- Preventing the risk of emergence of bacterial resistance associated with antibiotic therapy: what role for pharmacokinetic and pharmacodynamic data?Journal of Antimicrobial Chemotherapy, 2002
- Calcitonin precursors are reliable markers of sepsis in a medical intensive care unitCritical Care Medicine, 2000
- Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of Adults with Mild to Moderate Community-Acquired PneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin–clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcomeInternational Journal of Antimicrobial Agents, 1998